International Journal of Animal Breeding and Genetics Vol. 7 (2), pp. 001-010, February, 2018. © International Scholars Journals
Full Length Research Paper
Efficacy and toxicity of cymelarsan® in Nubian goats infected with Trypanosoma evansi
F. M. Youssif1*, O. S. A. Mohammed2 and T. Hassan3
1Central Veterinary Research Laboratories (CVRL) Khartoum-Sudan. P. O. Box 8067.
2Department of Medicine, Pharmacology and Toxicology- Faculty of Veterinary Medicine. Sudan University of Science and Technology. P. O. Box 407.
3Department of Medicine, Pharmacology and Toxicology- Faculty of Veterinary Medicine. University of Khartoum. P. O. Box 32.
Accepted 28 April, 2017
Nine groups of Nubian goats were infected with T. evansi. Groups 1 and 2 were used as negative and positive control respectively, groups 3, 4, 5 and 6 were given a single intramuscular dose of Cymelarsan® at the rate of 0.125, 0.25, 0.625, 1.25 mg/kg, respectively. Goats in groups 7 and 8 were each given intramuscular Cymelarsan® at the rate of 0.125 mg/kg twice/week for two weeks and 0.125 mg/kg daily for 8 days, respectively. Goats in groups 9 and 10 were each given the drug intramuscular at the rate of 0.25 mg/kg twice/week for two weeks and 0.25 mg/kg daily for 8 days respectively. Goats in group 2 showed clinical signs of trypanosomosis while infected goats of groups (4 - 5) signs disappeared. Goats of group 3 responded to the treatment but relapse occurred. Goats of groups (6 -10) were parasite free but expressed clinical signs of arsenic toxicosis. The haematological and serobiochemical changes were correlated with the clinical signs and pathology. Single dosages of 0.25–0.625 mg/kg wee recommended for treatment of T. evansi. Single dosage of 1.25 mg/kg and the multiple dosages were toxic and fatal. The drug has accumulative effect.
Key words: Nubian goats, Cymelarsan, efficacy, toxicity, T. evansi, Sudan.